Journal of Physiological Sciences 2013-03-01

Electrophysiological and pharmacological properties of GABAergic cells in the dorsal raphe nucleus.

Yoshihiro Gocho, Atsushi Sakai, Yuchio Yanagawa, Hidenori Suzuki, Fumihito Saitow

Index: J. Physiol. Sci. 63(2) , 147-54, (2013)

Full Text: HTML

Abstract

The dorsal raphe nucleus (DRN) is the origin of the central serotonin [5-hydroxytryptamine (5-HT)] system and plays an important role in the regulation of many physiological functions such as sleep/arousal, food intake and mood. In order to understand the regulatory mechanisms of 5-HT system, characterization of the types of neurons is necessary. We performed electrophysiological recordings in acute slices of glutamate decarboxylase 67-green fluorescent protein knock-in mice. We utilized this mouse to identify visually GABAergic cells. Especially, we examined postsynaptic responses mediated by 5-HT receptors between GABAergic and serotonergic cells in the DRN. Various current responses were elicited by 5-HT and 5-HT(1A) or 5-HT(2A/2C) receptor agonists in GABAergic cells. These results suggested that multiple 5-HT receptor subtypes overlap on GABAergic cells, and their combination might control 5-HT cells. Understanding the postsynaptic 5-HT feedback mechanisms may help to elucidate the 5-HT neurotransmitter system and develop novel therapeutic approaches.


Related Compounds

Related Articles:

Chemical genetics reveals a complex functional ground state of neural stem cells.

2007-05-01

[Nat. Chem. Biol. 3(5) , 268-273, (2007)]

5-HT1D receptor inhibits renal sympathetic neurotransmission by nitric oxide pathway in anesthetized rats.

2015-09-01

[Vascul. Pharmacol. 72 , 172-80, (2015)]

Pharmacological evidence that 5-HT1D activation induces renal vasodilation by NO pathway in rats.

2015-06-01

[Clin. Exp. Pharmacol. Physiol. 42 , 640-7, (2015)]

Serotonin 5-HT1A receptor in infancy-onset aggression: comparison with genetically defined aggression in adult rats.

2013-04-15

[Behav. Brain Res. 243 , 97-101, (2013)]

Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1Aactivity, Part 1

2009-01-01

[Eur. J. Med. Chem. 44 , 1710-7, (2009)]

More Articles...